204 related articles for article (PubMed ID: 28939005)
41. Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view.
Fuentes B
Med Clin (Barc); 2018 Apr; 150(7):275-281. PubMed ID: 29096968
[TBL] [Abstract][Full Text] [Related]
42. Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes.
Miao S; Dong X; Zhang X; Jing S; Zhang X; Xu T; Wang L; Du X; Xu H; Liu Y
J Diabetes; 2019 Aug; 11(8):684-689. PubMed ID: 30597747
[TBL] [Abstract][Full Text] [Related]
43. [The effect of antidiabetic treatment on the bone of patients with type 2 diabetes].
Karásek D
Vnitr Lek; 2016; 62(7-8):582-7. PubMed ID: 27627081
[TBL] [Abstract][Full Text] [Related]
44. Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis.
Benn M; Emanuelsson F; Tybjærg-Hansen A; Nordestgaard BG
Diabetologia; 2021 Jul; 64(7):1492-1503. PubMed ID: 33765180
[TBL] [Abstract][Full Text] [Related]
45. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease.
Zhang F; Ji L; Hong T; Guo L; Li Y; Zhu Z; Liu X; Liu F; Tang L; Zhang Y; Li J; Lü Q; Tong N
J Evid Based Med; 2022 Jun; 15(2):168-179. PubMed ID: 35715995
[TBL] [Abstract][Full Text] [Related]
46. Effects of glucose-lowering agents on ischemic stroke.
Avgerinos K; Tziomalos K
World J Diabetes; 2017 Jun; 8(6):270-277. PubMed ID: 28694927
[TBL] [Abstract][Full Text] [Related]
47. Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient.
Kotsis V; Jordan J; Stabouli S; Antza C; Micic D; Jelaković B; Schlaich MP; Nilsson PM; Kreutz R; Mancia G; Tsioufis K; Grassi G
J Hypertens; 2020 Mar; 38(3):377-386. PubMed ID: 31764586
[TBL] [Abstract][Full Text] [Related]
48. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs.
Shah SR; Iqbal SM; Alweis R; Roark S
Expert Rev Clin Pharmacol; 2019 Jan; 12(1):45-52. PubMed ID: 30488734
[TBL] [Abstract][Full Text] [Related]
49. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.
Eurich DT; McAlister FA; Blackburn DF; Majumdar SR; Tsuyuki RT; Varney J; Johnson JA
BMJ; 2007 Sep; 335(7618):497. PubMed ID: 17761999
[TBL] [Abstract][Full Text] [Related]
50. Emerging Targets for Cardiovascular Disease Prevention in Diabetes.
Stitziel NO; Kanter JE; Bornfeldt KE
Trends Mol Med; 2020 Aug; 26(8):744-757. PubMed ID: 32423639
[TBL] [Abstract][Full Text] [Related]
51. Antidiabetic therapies and Alzheimer disease.
Bendlin BB
Dialogues Clin Neurosci; 2019 Mar; 21(1):83-91. PubMed ID: 31607783
[TBL] [Abstract][Full Text] [Related]
52. Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients.
Lăcătușu CM; Grigorescu ED; Stătescu C; Sascău RA; Onofriescu A; Mihai BM
Medicina (Kaunas); 2019 Sep; 55(9):. PubMed ID: 31540142
[TBL] [Abstract][Full Text] [Related]
53. Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment.
Terlizzese P; Losurdo F; Iacoviello M; Aspromonte N
Heart Fail Rev; 2018 May; 23(3):469-479. PubMed ID: 29318412
[TBL] [Abstract][Full Text] [Related]
54. Metformin in the era of new antidiabetics.
Rajjoub Al-Mahdi EA; Barrios V; Zamorano JL
Future Cardiol; 2021 May; 17(3):475-485. PubMed ID: 33754810
[TBL] [Abstract][Full Text] [Related]
55. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.
Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988
[TBL] [Abstract][Full Text] [Related]
56. [Among adults with cardiovascular disease and BMI≥27kg/m
Lanthier L; Langlois MF; Plourde MÉ; Cauchon M
Rev Med Interne; 2024 Mar; 45(3):178-179. PubMed ID: 38228454
[No Abstract] [Full Text] [Related]
57. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes.
Yaribeygi H; Atkin SL; Pirro M; Sahebkar A
J Cell Physiol; 2019 Jun; 234(6):8286-8294. PubMed ID: 30417367
[TBL] [Abstract][Full Text] [Related]
58. Diabetes mellitus and multiple myeloma; common features of two distinct entities.
Tentolouris A; Ntanasis-Stathopoulos I; Eleftheriadou I; Malandrakis P; Tzeravini E; Gavriatopoulou M
Diabetes Metab Res Rev; 2022 Jul; 38(5):e3535. PubMed ID: 35555946
[TBL] [Abstract][Full Text] [Related]
59. Pharmacogenetics of Antidiabetic Drugs.
Srinivasan S; Yee SW; Giacomini KM
Adv Pharmacol; 2018; 83():361-389. PubMed ID: 29801583
[TBL] [Abstract][Full Text] [Related]
60. Diabetes Therapies for Dementia.
Moran C; Callisaya ML; Srikanth V; Arvanitakis Z
Curr Neurol Neurosci Rep; 2019 Jul; 19(8):58. PubMed ID: 31300920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
